Altimmune Inc (ALT)

$4.16 +0.10 (2.46%)
Market Cap 441.37M
Revenue (ttm) 20,000.00
Net Income (ttm) -95.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -475,300.00%
Debt to Equity Ratio 0.08
Volume 2,226,363
Avg Vol 2,800,418
Day's Range N/A - N/A
Shares Out 104.34M
Stochastic %K 52%
Beta 0.01
Analysts Strong Sell
Price Target $17.88

Company Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry: Biotechnology
Sector: Healthcare
Phone: 240 654 1450
Address:
910 Clopper Road, Suite 201S, Gaithersburg, United States
HedgeFundMgr
HedgeFundMgr Nov. 14 at 9:06 PM
$ALT Didn't she hold up well in the face of the "we're scared the Fed won't cut rates for us again in December" shenanigans? She held up quite well, imho. Wen b/o newz? lol 🤣
0 · Reply
VINCE_CARTER
VINCE_CARTER Nov. 14 at 9:06 PM
$ALT Impact p2 highlights: https://firstwordpharma.com/story/6518919
0 · Reply
Jacked_Nicholson
Jacked_Nicholson Nov. 14 at 9:05 PM
$ALT I didn't expect that today... I consider this as a win! Have a nice weekend!
0 · Reply
wildcard55
wildcard55 Nov. 14 at 9:05 PM
$ALT Closed up 1.4% for the week! :)
0 · Reply
minnesotafarmcountry
minnesotafarmcountry Nov. 14 at 9:03 PM
$ALT So essentially 300k+ volume in the last few minutes and doesn’t affect the price, either way? 😡😂
1 · Reply
TradeSun
TradeSun Nov. 14 at 9:02 PM
$ALT Ok, TY for the day, have a good weekend!☀️ 359k at the 🛎️ DP 66% Shares available still 150k Saluti!
1 · Reply
HattysRevenge
HattysRevenge Nov. 14 at 9:01 PM
$ALT FFSAF !
0 · Reply
Corpkcots
Corpkcots Nov. 14 at 9:01 PM
$ALT
0 · Reply
romanaround
romanaround Nov. 14 at 9:00 PM
$ALT Monday will be Moonday 🌓 I believe
1 · Reply
HattysRevenge
HattysRevenge Nov. 14 at 8:56 PM
$ALT Perfect for EOD ! https://www.youtube.com/watch?v=j-pcvD03sBA&list=RDuIPS4LyveJs&index=10
0 · Reply
Latest News on ALT
Altimmune: Probing Pemvi's MASH Data

Nov 14, 2025, 3:23 AM EST - 12 hours ago

Altimmune: Probing Pemvi's MASH Data

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

Nov 11, 2025, 8:51 AM EST - 3 days ago

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

Nov 7, 2025, 8:05 AM EST - 7 days ago

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 2:26 PM EST - 8 days ago

Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

Nov 6, 2025, 7:00 AM EST - 8 days ago

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

Altimmune to Participate in Two Upcoming Investor Conferences

Nov 5, 2025, 7:30 AM EST - 9 days ago

Altimmune to Participate in Two Upcoming Investor Conferences

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Nov 3, 2025, 7:30 AM EST - 11 days ago

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Oct 30, 2025, 7:30 AM EDT - 15 days ago

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

Oct 20, 2025, 7:30 AM EDT - 25 days ago

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

Oct 6, 2025, 10:09 AM EDT - 5 weeks ago

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Oct 5, 2025, 11:40 PM EDT - 5 weeks ago

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Oct 3, 2025, 9:50 AM EDT - 6 weeks ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Sep 30, 2025, 10:20 AM EDT - 6 weeks ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

Sep 29, 2025, 7:30 AM EDT - 6 weeks ago

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Sep 21, 2025, 8:39 AM EDT - 7 weeks ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

Sep 19, 2025, 10:27 AM EDT - 2 months ago

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

SLQT

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Sep 18, 2025, 8:45 AM EDT - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Sep 15, 2025, 7:30 AM EDT - 2 months ago

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Altimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 11:20 AM EDT - 2 months ago

Altimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade)

Aug 27, 2025, 5:17 PM EDT - 2 months ago

Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade)

Altimmune to Participate in Upcoming Investor Conferences

Aug 26, 2025, 7:30 AM EDT - 2 months ago

Altimmune to Participate in Upcoming Investor Conferences

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Aug 19, 2025, 7:30 AM EDT - 3 months ago

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

Aug 15, 2025, 12:06 PM EDT - 3 months ago

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

Altimmune, Inc. (ALT) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 4:44 PM EDT - 3 months ago

Altimmune, Inc. (ALT) Q2 2025 Earnings Call Transcript

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Aug 13, 2025, 2:57 PM EDT - 3 months ago

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Altimmune Announces Second Quarter 2025 Financial Results and Business Update

Aug 12, 2025, 7:00 AM EDT - 3 months ago

Altimmune Announces Second Quarter 2025 Financial Results and Business Update

Altimmune Board of Directors Appoints Jerry Durso as Chairman

Aug 11, 2025, 7:30 AM EDT - 3 months ago

Altimmune Board of Directors Appoints Jerry Durso as Chairman

Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

Aug 5, 2025, 7:30 AM EDT - 3 months ago

Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm

Jul 19, 2025, 2:30 PM EDT - 4 months ago

ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm

Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)

Jul 9, 2025, 7:30 AM EDT - 4 months ago

Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)

Altimmune's Fatty Liver Candidate Faces Differentiation Doubts

Jun 27, 2025, 2:39 PM EDT - 5 months ago

Altimmune's Fatty Liver Candidate Faces Differentiation Doubts

HedgeFundMgr
HedgeFundMgr Nov. 14 at 9:06 PM
$ALT Didn't she hold up well in the face of the "we're scared the Fed won't cut rates for us again in December" shenanigans? She held up quite well, imho. Wen b/o newz? lol 🤣
0 · Reply
VINCE_CARTER
VINCE_CARTER Nov. 14 at 9:06 PM
$ALT Impact p2 highlights: https://firstwordpharma.com/story/6518919
0 · Reply
Jacked_Nicholson
Jacked_Nicholson Nov. 14 at 9:05 PM
$ALT I didn't expect that today... I consider this as a win! Have a nice weekend!
0 · Reply
wildcard55
wildcard55 Nov. 14 at 9:05 PM
$ALT Closed up 1.4% for the week! :)
0 · Reply
minnesotafarmcountry
minnesotafarmcountry Nov. 14 at 9:03 PM
$ALT So essentially 300k+ volume in the last few minutes and doesn’t affect the price, either way? 😡😂
1 · Reply
TradeSun
TradeSun Nov. 14 at 9:02 PM
$ALT Ok, TY for the day, have a good weekend!☀️ 359k at the 🛎️ DP 66% Shares available still 150k Saluti!
1 · Reply
HattysRevenge
HattysRevenge Nov. 14 at 9:01 PM
$ALT FFSAF !
0 · Reply
Corpkcots
Corpkcots Nov. 14 at 9:01 PM
$ALT
0 · Reply
romanaround
romanaround Nov. 14 at 9:00 PM
$ALT Monday will be Moonday 🌓 I believe
1 · Reply
HattysRevenge
HattysRevenge Nov. 14 at 8:56 PM
$ALT Perfect for EOD ! https://www.youtube.com/watch?v=j-pcvD03sBA&list=RDuIPS4LyveJs&index=10
0 · Reply
HarryScrotmsRashy
HarryScrotmsRashy Nov. 14 at 8:55 PM
$ALT I know not today but we have to work towards a 500 million MC.
1 · Reply
BioRich
BioRich Nov. 14 at 8:52 PM
$ALT Make sure to check those emails AH. PR time?
0 · Reply
RichiePostCounter
RichiePostCounter Nov. 14 at 8:51 PM
$ALT Think Christophe is related to Stephan Engels lol
1 · Reply
SuperPuncher
SuperPuncher Nov. 14 at 8:50 PM
$ALT please end the day on an even +6% so I can show the officer why I had to drink all 6 of them when I get pulled over
1 · Reply
VINCE_CARTER
VINCE_CARTER Nov. 14 at 8:43 PM
$ALT interested to see VWAP for today
0 · Reply
theRealTruth22
theRealTruth22 Nov. 14 at 8:42 PM
$ALT great news and great companies typically release market moving data Monday mornings pre-market followed by a CC. Only a few Mondays left!
2 · Reply
lrk3383
lrk3383 Nov. 14 at 8:40 PM
$ALT https://stocktwits.com/news/equity/markets/novo-nordisk-brings-back-former-ceo-to-lead-board/cLPQlkLRE4v
0 · Reply
dcrown
dcrown Nov. 14 at 8:38 PM
$ALT before end of December NVO release the news
0 · Reply
GreenEnergy2022
GreenEnergy2022 Nov. 14 at 8:34 PM
$ALT Before end of December: 48w EoP2 FDA Oral BTD
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Nov. 14 at 8:29 PM
$ALT deals are being cut everywhere-$CDTX BO by $MRK for $9B
1 · Reply
TradeSun
TradeSun Nov. 14 at 8:25 PM
$ALT And NVO lost its battle against PFE. So $ 10B more on hand... Uff🫣! https://www.marketscreener.com/news/novo-nordisk-shareholders-approve-new-chair-board-members-ce7d5fd2dd8aff20 https://www.marketscreener.com/news/novo-nordisk-elects-new-chair-vice-chair-in-board-shakeup-ce7d5fd2dd8ff72d https://www.marketscreener.com/news/novo-nordisk-shareholders-approve-lars-rebien-sorensen-as-new-chairman-ce7d5fd2da8cf62c A good time to invest in $NVO if they were to win the race for Pemvi... (last 16 months)
2 · Reply
ItIsGoTime
ItIsGoTime Nov. 14 at 8:22 PM
$ALT "Importantly, there was statistical significance on weight loss by week 24, so this is the first glucagon GLP-1 that leads to both histological improvement as well as weight loss at week 24."
1 · Reply